{"id":"NCT00441103","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis","officialTitle":"A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-11","completion":"2009-02","firstPosted":"2007-02-28","resultsPosted":"2010-07-05","lastUpdate":"2014-07-09"},"enrollment":180,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"DRUG","name":"Rebif® New Formulation (IFN-beta-1a, RNF)","otherNames":["IFN-beta-1a"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Rebif® New Formulation (IFN-beta-1a, RNF)","otherNames":["IFN-beta-1a"]}],"arms":[{"label":"Rebif® New Formulation (IFN-beta-1a, RNF)","type":"EXPERIMENTAL"},{"label":"Placebo/RNF","type":"PLACEBO_COMPARATOR"}],"summary":"General Note: throughout this record, \"Rebif® New Formulation\" is used for historical and consistency purposes.\n\nObjectives:\n\nPrimary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a \\[IFN-beta-1a\\], RNF), compared to placebo, in subjects with Relapsing Remitting Multiple Sclerosis and active disease by means of Magnetic Resonance Imaging (MRI) at the end of 16 weeks of treatment Secondary: To evaluate the efficacy of RNF by comparing the mean number of combined unique (CU) lesions per scan per subject between the initial 16 weeks of placebo treatment and 24 weeks of RNF treatment in the same subjects, originally randomized to placebo.\n\nPrimary Endpoints: The primary endpoint is the difference between the number of CU active MRI lesions at Week 16 in the RNF group (Group 1) versus the placebo group (Group 2).\n\nSecondary Endpoints: The secondary endpoint is the difference in the mean number of CU active MRI lesions per scan per subject over the following treatment periods: Study Day 1 - Week 16 versus Weeks 17 - 40 for the subjects randomized to Group 2.","primaryOutcome":{"measure":"Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16","timeFrame":"16 Weeks","effectByArm":[{"arm":"Rebif® New Formulation (IFN-beta-1a, RNF)","deltaMin":0.9,"sd":1.4},{"arm":"Placebo/RNF","deltaMin":3,"sd":4.1}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20200197","21880336","33329329"],"seeAlso":["http://www.mslifelines.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":120},"commonTop":["Influenza like illness","Headache","Injection site erythema","Injection site pain","Pyrexia"]}}